Community Research and Development Information Service - CORDIS

Horizon 2020 project information and now also report summaries are available on CORDIS. All H2020 projects can be downloaded from the EU Open Data Portal .

My refinements

Download results of this page

Refine by:

Content type

Project (789)
Result in Brief (108)
Report Summary (521)


Albania (2)
Argentina (2)
Australia (18)
Austria (95)
Bangladesh (1)
Belgium (199)
Benin (1)
Bosnia and Herzegovina (1)
Brazil (4)
Bulgaria (11)
Burkina Faso (1)
Cambodia (1)
Canada (18)
China (3)
Colombia (3)
Croatia (20)
Cuba (2)
Cyprus (14)
Czech Republic (37)
Côte d’Ivoire (1)
Denmark (141)
Ecuador (1)
Estonia (24)
Finland (97)
Former Yugoslav Republic of Macedonia (6)
France (294)
French Polynesia (1)
Gabon (2)
Germany (396)
Ghana (1)
Greece (91)
Hungary (38)
Iceland (18)
India (3)
Ireland (83)
Israel (76)
Italy (317)
Jamaica (1)
Japan (1)
Kosovo (3)
Kyrgyzstan (1)
Latvia (15)
Lithuania (3)
Luxembourg (23)
Malawi (2)
Malta (2)
Mexico (2)
Moldova (2)
Montenegro (2)
Mozambique (2)
Nepal (2)
Netherlands (324)
New Caledonia (1)
Norway (64)
Pakistan (2)
Peru (1)
Poland (56)
Portugal (75)
Romania (25)
Russia (1)
Senegal (4)
Serbia (17)
Slovakia (13)
Slovenia (39)
South Africa (6)
South Korea (6)
Spain (345)
Sri Lanka (1)
Sweden (167)
Switzerland (134)
Taiwan (5)
Tajikistan (1)
Tanzania (4)
Turkey (18)
Uganda (6)
Ukraine (1)
United Kingdom (412)
United States (73)
Vietnam (1)
Zambia (1)

Advanced search

Search projects and results

Results 1 - 10 of 1418
12 3 4 5 6 7 8 9 10 > >| 
Periodic Reporting for period 1 - IB4SD-TRISTAN (Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment (IB4SD-TRISTAN))
"Before new drugs are marketed, regulatory authorities must be satisfied that the benefits from the new drug outweigh any harms that might occur. The characterisation and amelioration of potential harms is called Drug Safety Assessment.Biomarkers are important in Drug Safety...
Programme: H2020-EU.3.1.
Record Number: 231750
Last updated on: 2018-06-15
Development of DIALIVE, a novel Liver Dialysis Device for the treatment of patients with Acute on Chronic Liver Failure (ACLF)
ID: 733057
Start date: 2017-01-01, End date: 2020-09-30
Liver disease incidence is increasing and about 170K patients die from liver failure each year in Europe. In liver failure, the accumulation of protein bound toxins and increased susceptibility to infection cause multiorgan failure and death. Liver transplantation is the only...
Programme: H2020-EU.3.1.3.
Record Number: 207215
Last updated on: 2017-08-04
Periodic Reporting for period 1 - ADAPTED (Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development)
ADAPTED has a focussed set of objectives aimed at; 1. Clarifying the role of APOE as a risk factor in the development of AD2. Identifying promising entry points (targets) for the treatment of AD 3. Generate and validate selected high value APOE-related model systems4. Uncover...
Programme: H2020-EU.3.1.7.
Record Number: 231748
Last updated on: 2018-06-15
Periodic Reporting for period 2 - EBOVAC2 (Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II)
Combining the expertise and capabilities of global research institutions, non-government organizations and the pharmaceutical industry has been critical to help address the Ebola public health challenge.The Ebola vaccine projects - EBOVAC1, EBOVAC2, EBODAC and EBOMAN - are a...
Programme: H2020-EU.
Record Number: 230029
Last updated on: 2018-05-22
Periodic Reporting for period 1 - PHAGO (Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33)
Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with progressive loss of nerve cells and their connectivity in the brain. Today, over 46 million people live with dementia worldwide and this number is estimated to increase to 131.5 million by...
Programme: H2020-EU.3.1.7.
Record Number: 231747
Last updated on: 2018-06-15
Periodic Reporting for period 1 - RHAPSODY (Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification)
Diabetes is subdivided into Type 1 Diabetes (T1D) and Type 2 Diabetes mellitus (T2D). T1D accounts for about 10% of all patients. T2D, which accounts for about 80-90% of all patients, is very heterogeneous, but the extent of this diversity is not known. RHAPSODY explores...
Programme: H2020-EU.
Record Number: 232104
Last updated on: 2018-06-22
Periodic Reporting for period 2 - EBODAC (Communication strategy and tools for optimizing the impact of Ebola vaccination deployment.)
The Ebola virus disease (EVD) epidemic has infected more than 28.000 people and killed more than 11.000 from March 2014 to December 2015, the vast majority of them in 3 West African countries: Guinea, Liberia and Sierra Leone (WHO Ebola Situation Report June 10, 2016). No...
Programme: H2020-EU.
Record Number: 232106
Last updated on: 2018-06-22
Periodic Reporting for period 1 - PRISM (Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD)
Most mental health conditions are still classified and diagnosed solely based on the symptoms observed, as there are few objective biomarkers for these conditions as there are for other conditions, such as diabetes. Many different neuropsychiatric diseases share symptoms...
Programme: H2020-EU.
Record Number: 231719
Last updated on: 2018-06-15
Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
ID: 115881
Start date: 2016-04-01, End date: 2020-03-31
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and...
Programme: H2020-EU.
Record Number: 209450
Last updated on: 2017-03-27
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II
ID: 115861
Start date: 2014-12-01, End date: 2019-11-30
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.This will be done by:1. Carrying out translational studies to link vaccine elicited immune responses in humans...
Programme: H2020-EU.
Record Number: 209445
Last updated on: 2017-07-28
12 3 4 5 6 7 8 9 10 > >| 
List retrieved on: 2018-08-15
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top